science lab

To reformulate metered-dose inhaler

Cambridge company Mundipharma and Wiltshire-based Vectura, owned by Philip Morris International, have announced plans to reformulate the flutiform pressurised metered-dose inhaler as a commitment to reducing the product’s carbon footprint.

Mundipharma and Vectura will now progress development of the reformulation of flutiform following long-term collaboration, planning and lab-scale development work.

The reformulation will ultimately ensure a comparable effective product for patients and further reduce its impact on the environment.